# US 2022/0033772 A1 · Factor rich products from umbilical cord mesenchymal stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033772 A1
- Document ID: US20220033772A1
- Status: Published application
- Kind: A1
- Application number: 17/501,775
- Filed: 2021-10-14
- Published: 2022-02-03
- Earliest claimed: 2015-09-02
- Assignees: Restem LLC
- Applicants: Restem LLC
- Inventors: Rafael Gonzalez; Toai Nguyen
- Web page: https://patentgrep.com/patent/US20220033772A1

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- C12N 2501/10: Growth factors
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/148: Transforming growth factor alpha [TGF-a]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/17: Angiopoietin
- C12N 2501/21: Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/23: Interleukins [IL]
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2308: Interleukin-8 (IL-8)
- C12N 2501/2318: Interleukin-18 (IL-18)
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2502/025: extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Factor rich compositions produced from umbilical cord (UC) mesenchymal stem cells (MSCs) are described. Secretory UC MSCs in serum free culture conditions produce a factor rich conditioned medium which may be concentrated and filtered to obtain clinical grade products.

## Claims

### Claim 1

A factor rich composition derived from umbilical cord (UC) mesenchymal stem cells (MSCs) cultured without serum or exogenous growth factors comprising:
a. a population of exosomes at a concentration of at least 22 billion per milliliter (ml);
b. said population of exosomes at an average size of about 133.4 nanometers (nm);
c. a growth factor selected from the group consisting of stem cell factor (SCF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF) and combinations thereof;
d. said growth factors at a concentration of at least 20-2000 picogram (pg)/ml;
e. a cytokine or chemokine selected from the group consisting of interferon gamma, (INF-γ), interleukins (IL) 3, 6, 18, IL-4 7, 8, macrophage inflammatory protein-1 beta (MIP1β), monocyte chemoattractant protein-1 (MCP1) and tumor necrosis factor alpha (TNFα) and combinations thereof;
f. a glycosaminoglycan (GAG) selected from the group consisting of hyaluronic acid (HA) and chondroitin sulfate (CS);
g. a collagen selected from the group consisting of collagen I and collage III.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said HA is present at a concentration of at least 1 microgram (μg)/ml.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said HA is of molecular weight up to about 2500 kilodaltons (kDa).

### Claim 4 (depends on 1)

The composition of claim 1, wherein said collagen is present at a concentration of at least 0.281 microgram (mg)/ml.

### Claim 5 (depends on 1)

The composition of claims 1, wherein the product is provided in a physical state selected from the group consisting of liquid, frozen, lyophilized.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the product is sterile.